Top Markets
#1 Siacoin Siacoin +27.05%
#2 DogBull DogBull +26.93%
#3 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#4 Cash Cat Cash Cat +23.26%
#5 MarsCoin MarsCoin +10.63%
#6 Akedo Akedo +9.83%
#7 The Bitcoin Bull The Bitcoin Bull +9.42%
#8 Pons Pons +9.24%
#9 Bitway Bitway +8.53%
#10 Asteroid Shiba Asteroid Shiba +8.32%
Coin of the day
Siacoin Siacoin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Peringkat dalam Saham #14120
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Harga Saham
$1.46
Terakhir disinkronkan: 2026-07-28
Kapitalisasi Pasar
$435.25M
Perubahan (1 hari)
-2.34%
Perubahan (1 tahun)
-25.65%
Negara
TW
Perdagangan EirGenix Inc. (6589)

Kategori

Healthcare
Rasio P/E untuk EirGenix Inc. (6589)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari EirGenix Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk EirGenix Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.